Aerie Pharmaceuticals Elects James Mazzo to the Company’s Board of Directors

  Aerie Pharmaceuticals Elects James Mazzo to the Company’s Board of Directors

Business Wire

BEDMINSTER, N.J. & RESEARCH TRIANGLE PARK, N.C. & NEWPORT BEACH, Calif. --
June 11, 2014

Aerie Pharmaceuticals, Inc. (Nasdaq:AERI) today announced that James Mazzo has
been elected to the Company’s Board of Directors, effective June 11, 2014. Mr.
Mazzo brings an impressive track record of leadership roles within the
ophthalmic industry, including as the former head of Abbott Medical Optics,
and currently serves as Operating Partner at Versant Ventures.

“We’re excited to welcome Jim Mazzo to the Board. Jim offers a wealth of
experience in commercializing innovative products and technologies across a
broad range of ophthalmology applications,” said Vicente Anido, Ph.D.,
Chairman and Chief Executive Officer. “His expertise in building
pre-commercial pipelines will prove highly beneficial as we advance our
triple-action product candidate, Rhopressa™, into Phase 3 clinical trials
early next quarter, and report Phase 2b data for our quadruple-action
candidate, Roclatan™, in late June or early July.”

Mr. Mazzo’s 35-year career in the healthcare industry includes seven years as
Chairman, President and CEO of Advanced Medical Optics (AMO), which was sold
to Abbott Laboratories in 2009 for $2.8 billion. Previously, he had a more
than 20-year tenure at Allergan in a variety of leadership roles, eventually
leading the spinoff of AMO from Allergan in 2002. Upon taking the helm at AMO,
Mr. Mazzo expanded the company into an industry-leading, publicly traded
corporation with more than $1 billion in annual revenues. Following the
acquisition of AMO, Mr. Mazzo became Senior Vice President at Abbott, in
addition to serving as President of Abbott Medical Optics, the successor of
AMO within Abbott.

Currently, in addition to his position as Operating Partner at Versant
Ventures, Mr. Mazzo serves as Executive Chairman and CEO of Versant portfolio
company AcuFocus, which specializes in corneal inlays and is known for its
revolutionary KAMRA inlay for the treatment of presbyopia. He also is the
Executive Chairman of Neurotech Pharmaceuticals, which is advancing
encapsulated cell technology as a drug delivery platform for retinal
degenerative diseases. Further, Mr. Mazzo is a Public Trustee on the Governing
Board of the American Society of Cataract and Refractive Surgery (ASCRS). He
received his B.S. degree from California State University, Long Beach.

“I am highly impressed with Aerie’s differentiated glaucoma product portfolio.
Aerie’s lead product candidates, Rhopressa™ and Roclatan™, have already shown
very promising results, including the novel ability to target the diseased
tissue, or main drain of the eye, along with multiple additional mechanisms of
action to reduce intraocular pressure," said James Mazzo. “I very much look
forward to working closely with the Aerie team in helping to further advance
these innovative product candidates, each of which has the potential to change
the future landscape of glaucoma therapies.”

About Aerie Pharmaceuticals

Aerie is a clinical-stage pharmaceutical company focused on the discovery,
development and commercialization of first-in-class glaucoma therapies. The
Company is preparing for two Phase 3 registration trials in the U.S. where the
primary efficacy endpoint will be to demonstrate non-inferiority of IOP
lowering for Rhopressa™ (dosed once daily and twice daily) compared to timolol
(dosed twice daily), along with a third safety-only trial in Canada. The
Company is also currently executing a Phase 2b clinical trial where the
primary efficacy endpoint is to demonstrate superiority of Roclatan™ to each
of its components.

Forward-Looking Statements

This press release contains forward-looking statements for purposes of the
safe harbor provisions of the Private Securities Litigation Reform Act of
1995. We may, in some cases, use terms such as "predicts," "believes,"
"potential," "proposed," "continue," "estimates," "anticipates," "expects,"
"plans," "intends," "may," "could," "might," "will," "should" or other words
that convey uncertainty of future events or outcomes to identify these
forward-looking statements. Forward-looking statements include statements
regarding our intentions, beliefs, projections, outlook, analyses or current
expectations concerning, among other things: the success, timing and cost of
our ongoing and anticipated preclinical studies and clinical trials for our
current product candidates, including statements regarding the timing of
initiation and completion of the studies and trials; our expectations
regarding the clinical effectiveness of our product candidates and results of
our clinical trials; the timing of and our ability to obtain and maintain U.S.
Food and Drug Administration or other regulatory authority approval of, or
other action with respect to, our product candidates; our expectations related
to the use of proceeds from our initial public offering; our estimates
regarding anticipated capital requirements and our needs for additional
financing; the potential advantages of our product candidates; and our ability
to protect our proprietary technology and enforce our intellectual property
rights. By their nature, forward-looking statements involve risks and
uncertainties because they relate to events, competitive dynamics and industry
change, and depend on regulatory approvals and economic circumstances that may
or may not occur in the future or may occur on longer or shorter timelines
than anticipated. We discuss many of these risks in greater detail under the
heading "Risk Factors" in the quarterly and annual reports that we file with
the Securities and Exchange Commission (SEC). Forward-looking statements are
not guarantees of future performance and our actual results of operations,
financial condition and liquidity, and the development of the industry in
which we operate may differ materially from the forward-looking statements
contained in this press release. Any forward-looking statements that we make
in this press release speak only as of the date of this press release. We
assume no obligation to update our forward-looking statements whether as a
result of new information, future events or otherwise, after the date of this
press release.

Contact:

Aerie Pharmaceuticals
Richard Rubino, 908-470-4320
rrubino@aeriepharma.com
or
Burns McClellan, Inc. on behalf of Aerie Pharmaceuticals
Angeli Kolhatkar – Investors
akolhatkar@burnsmc.com
Justin Jackson – Media
jjackson@burnsmc.com
Both: 212-213-0006
 
Press spacebar to pause and continue. Press esc to stop.